表紙
市場調查報告書
商品編碼
974098

植物性醫藥品·植物來源醫藥品的全球市場(2020年∼2024年)

Global Botanical and Plant-Derived Drugs Market 2020-2024

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

植物性醫藥品·植物來源醫藥品的市場規模在2020年∼2024年的預測期間內,預計將以7%的年複合成長率增長,並成長到136億7,000萬美元。

市場成長的主要因素有政府主動行動的增加,與傳統藥物有關的限制以及對有效治療慢性疾病的需求不斷增長。此外,政府主動性的提高有望促進市場增長。

這份報告提供植物性醫藥品·植物來源醫藥品的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,各類型·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模(2019年)
  • 市場預測(2019年∼2024年)

波特的五力分析

各類型

  • 市場區隔
  • 各類型比較
  • 植物來源
  • 植物性
  • 各類型的市場機會

客戶形勢

各地區

  • 市場區隔
  • 各地區比較
  • 亞洲
  • 歐洲
  • 北美
  • 其他地區
  • 主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況
  • 競爭模式

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck KGaA
  • Mitsubishi Chemical Corp.
  • Novartis AG
  • Pfizer Inc.
  • Pierre Fabre SA
  • Sanofi

附錄

目錄
Product Code: IRTNTR45751

Technavio has been monitoring the botanical and plant-derived drugs market and it is poised to grow by $ 13.67 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on the botanical and plant-derived drugs market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in government initiatives, limitations associated with conventional drugs, and growing demand for effective treatment of chronic disorders. In addition, an increase in government initiatives is anticipated to boost the growth of the market as well.

The botanical and plant-derived drugs market analysis includes type segment and geographical landscapes.

Technavio's botanical and plant-derived drugs market is segmented as below:

By Type

  • Plant-derived drugs
  • Botanical drugs

By Geographical Landscapes

  • Asia
  • Europe
  • North America
  • ROW

This study identifies the transformation of the regulatory landscape in the US as one of the prime reasons driving the botanical and plant-derived drugs market growth during the next few years. Also, the growing focus on the development of drugs for new indications and the emergence of new entrants will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our botanical and plant-derived drugs market report covers the following areas:

  • Botanical and plant-derived drugs market sizing
  • Botanical and plant-derived drugs market forecast
  • Botanical and plant-derived drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading botanical and plant-derived drugs market vendors that include Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGaA, Mitsubishi Chemical Corp., Novartis AG, Pfizer Inc., Pierre Fabre SA, and Sanofi. Also, the botanical and plant-derived drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Plant-derived drugs - Market size and forecast 2019-2024
  • Botanical drugs - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • North America - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive Scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck KGaA
  • Mitsubishi Chemical Corp.
  • Novartis AG
  • Pfizer Inc.
  • Pierre Fabre SA
  • Sanofi

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Plant-derived drugs - Market size and forecast 2019-2024 ($ million)
  • 24: Plant-derived drugs - Year-over-year growth 2019-2024 (%)
  • 25: Botanical drugs - Market size and forecast 2019-2024 ($ million)
  • 26: Botanical drugs - Year-over-year growth 2019-2024 (%)
  • 27: Market opportunity by Type
  • 28: Customer landscape
  • 29: Market share by geography 2019-2024 (%)
  • 30: Geographic comparison
  • 31: Asia - Market size and forecast 2019-2024 ($ million)
  • 32: Asia - Year-over-year growth 2019-2024 (%)
  • 33: Europe - Market size and forecast 2019-2024 ($ million)
  • 34: Europe - Year-over-year growth 2019-2024 (%)
  • 35: North America - Market size and forecast 2019-2024 ($ million)
  • 36: North America - Year-over-year growth 2019-2024 (%)
  • 37: ROW - Market size and forecast 2019-2024 ($ million)
  • 38: ROW - Year-over-year growth 2019-2024 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: Bayer AG - Overview
  • 48: Bayer AG - Business segments
  • 49: Bayer AG - Key offerings
  • 50: Bayer AG - Key customers
  • 51: Bayer AG - Segment focus
  • 52: Boehringer Ingelheim International GmbH - Overview
  • 53: Boehringer Ingelheim International GmbH - Business segments
  • 54: Boehringer Ingelheim International GmbH - Key offerings
  • 55: Boehringer Ingelheim International GmbH - Key customers
  • 56: Boehringer Ingelheim International GmbH - Segment focus
  • 57: GlaxoSmithKline Plc - Overview
  • 58: GlaxoSmithKline Plc - Business segments
  • 59: GlaxoSmithKline Plc - Key offerings
  • 60: GlaxoSmithKline Plc - Key customers
  • 61: GlaxoSmithKline Plc - Segment focus
  • 62: Johnson & Johnson - Overview
  • 63: Johnson & Johnson - Business segments
  • 64: Johnson & Johnson - Key offerings
  • 65: Johnson & Johnson - Key customers
  • 66: Johnson & Johnson - Segment focus
  • 67: Merck KGaA - Overview
  • 68: Merck KGaA - Business segments
  • 69: Merck KGaA - Key offerings
  • 70: Merck KGaA - Key customers
  • 71: Merck KGaA - Segment focus
  • 72: Mitsubishi Chemical Corp. - Overview
  • 73: Mitsubishi Chemical Corp. - Product and service
  • 74: Mitsubishi Chemical Corp. - Key offerings
  • 75: Mitsubishi Chemical Corp. - Key customers
  • 76: Mitsubishi Chemical Corp. - Segment focus
  • 77: Novartis AG - Overview
  • 78: Novartis AG - Business segments
  • 79: Novartis AG - Key offerings
  • 80: Novartis AG - Key customers
  • 81: Novartis AG - Segment focus
  • 82: Pfizer Inc. - Overview
  • 83: Pfizer Inc. - Business segments
  • 84: Pfizer Inc. - Key offerings
  • 85: Pfizer Inc. - Key customers
  • 86: Pfizer Inc. - Segment focus
  • 87: Pierre Fabre SA - Overview
  • 88: Pierre Fabre SA - Business segments
  • 89: Pierre Fabre SA - Key offerings
  • 90: Pierre Fabre SA - Key customers
  • 91: Pierre Fabre SA - Segment focus
  • 92: Sanofi - Overview
  • 93: Sanofi - Business segments
  • 94: Sanofi - Key offerings
  • 95: Sanofi - Key customers
  • 96: Sanofi - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations